Mark A Little

ORCID: 0000-0001-6003-397X · 1 paper in corpus · active 2025
2025
HRB Open Research ·doi:10.12688/hrbopenres.14159.1

Background: Avacopan, a selective complement 5a receptor (C5aR) antagonist, is used for the treatment of severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in combination with rituximab or cyclophosphami…